A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Name: A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Published: 2021
License: Public Domain

Hoffmann-La Roche · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

neovascular age-related macular degeneration (namd), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Related documents